Glomerulonephritis


Book Description

This Handbook serves as a convenient, state-of-the-art and comprehensive resource on the pathogenesis, diagnosis, and treatment of glomerular diseases. Clinical approaches, modalities and challenges are provided, along with new developments since the publication of Kidney Disease Improving Global Outcomes (KDIGO): Glomerulonephritis. Chapters dedicated to glomerular diseases mirror the current classification schemes used by Nephrologists and Pathologists and will include definition and natural history, epidemiology, clinical manifestations, pathology, diagnosis, differential diagnosis, treatment (algorithms when appropriate), prognosis and future prospects and current direction of research. Contributing authors consist of internationally renowned glomerulonephritis experts, renal pathologists and clinical nephrologists who are engaged in the management of glomerular diseases in clinical pediatric and internal medicine practices. Glomerulonephritis fills a considerable knowledge gap for general nephrologists, providers involved with the care of patients with glomerular diseases, and researchers. It should also be of value to medical students, interns, residents and fellows, as well as all clinicians engaged in medical education.




Hematology


Book Description




Waldenström’s Macroglobulinemia


Book Description

This book sheds new light on clinical, biological and therapeutic data on the rare disease Waldenström’s Macroglobulinemia (WM) with the participation of widely-recognized experts, involved in this field. It represents the efforts of physicians, scientists and patients, all around the world, to better understand and cure this rare disease. Considerable advances in the diagnosis, treatment indications, response criteria, prognostic factors and treatment options have been made since Dr Jan Waldenström first reported this “new syndrome“ 70 years ago. Particularly instrumental in advancing of our understanding of WM have been the eight international workshops devoted to this disease. New, exciting molecular data have recently been reported, allowing us to revisit the oncogenic events leading to WM B-cell proliferation and to use newly available compounds targeting oncogenic pathways.




Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues


Book Description

This is the third volume in the new World Health Organization series on histological and genetic typing of tumours. Tumours of the haematopoietic and lymphoid tissues are covered. This was a collaborative project of the European Association for Haematolpathology and the Society for Haematopathology and others. The WHO classification is based on the principles defined in the Revised European-American Classification of Lymphoid Neoplasms (REAL) classification. Over 50 pathologists from around the world were involved in the project and proponents of all major lymphoma and leukaemia classifications have agreed to accept the WHO as the standard classification of haematological malignancies. So this classification represents the first true world wide concensus of haematologic malignancies. Colour photographs, magnetic resonance and ultrasound images and CT scans are included.







Fast Facts for Patients: Waldenström Macroglobulinemia


Book Description

Waldenström macroglobulinemia (shortened to WM) is a rare blood cancer. WM usually progresses slowly; some people do not show symptoms for several years after diagnosis. A person who does not have symptoms usually does not need treatment, but active monitoring is essential so that treatment can be started as soon as it is needed. Although there is no cure for WM, different treatment options can keep the disease under control for many years in a lot of people. Eventually, the treatments tend to lose their effect. New therapies are being tested in clinical trials across the world, with promising results. Table of Contents: • What is Waldenström macroglobulinemia? How will WM affect me? Who is in my care team? What tests will I need to have? Common feelings when diagnosed • Helping yourself • Active monitoring • Starting treatment • Types of treatment • What are supportive treatments? How do I know if treatment has worked? Follow-up after treatment • When WM comes back • Research and new treatments • Understanding WM




The Saint-Chopra Guide to Inpatient Medicine


Book Description

THE DEFINITIVE GUIDE TO INPATIENT MEDICINE, UPDATED AND EXPANDED FOR A NEW GENERATION OF STUDENTS AND PRACTITIONERS A long-awaited update to the acclaimed Saint-Frances Guides, the Saint-Chopra Guide to Inpatient Medicine is the definitive practical manual for learning and practicing inpatient medicine. Its end-to-end coverage of the specialty focuses on both commonly encountered problems and best practices for navigating them, all in a portable and user-friendly format. Composed of lists, flowcharts, and "hot key" clinical insights based on the authors' decades of experience, the Saint-Chopra Guide ushers clinicians through common clinical scenarios from admission to differential diagnosis and clinical plan. It will be an invaluable addition -- and safety net -- to the repertoire of trainees, clinicians, and practicing hospitalists at any stage of their career.







Fast Facts: Waldenström Macroglobulinemia


Book Description

Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma characterized by the presence of an immunoglobulin M (IgM) monoclonal protein. WM is a chronic, indolent disease, which can remain undiagnosed for years. A better understanding of the role of signaling pathways in the development of the disease and the identification of clinical and genetic markers have driven the development of targeted therapeutic strategies, improving overall survival.




Multiple Myeloma and Other Plasma Cell Neoplasms


Book Description

This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find Multiple Myeloma and Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management.